Market Place
Sourcing Support
Ocular Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
13 Dec 2024 //
GLOBENEWSWIRE
Ocular Therapeutix to Present at J.P. Morgan Healthcare Conference
10 Dec 2024 //
GLOBENEWSWIRE
Ocular to Participate in December Investor & Scientific Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ Reports Q3 2024 Results & Business Highlights
14 Nov 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Present at Jefferies & Ophthalmology Summit
13 Nov 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ Appoints Namrata as Chief Business Officer
12 Nov 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Report Q3 2024 Results on November 14, 2024
06 Nov 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Accelerated Timelines For SOL-1 Trial In Wet AMD
15 Oct 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Present at October Ophthalmology Meetings
09 Oct 2024 //
GLOBENEWSWIRE
Ocular Reports Inducement Grant Under Nasdaq LR 5635(c)(4)
09 Oct 2024 //
GLOBENEWSWIRE
Ocular Therapeutix To Present At UBS Ophthalmology Day 2024
25 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Reports Inducement Grant
12 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Present at September Retina Meetings
05 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Present at Two Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Reports Inducement Grants
09 Aug 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Receives FDA Feedback On SOL-R Trial For Wet AMD
07 Aug 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ Reports Second Quarter 2024 Results
07 Aug 2024 //
GLOBENEWSWIRE
Ocular Therapeutix To Report Q2 2024 Results On August 7
31 Jul 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Enrolls First Patients In Phase 3 SOL-R Wet AMD Study
30 Jul 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Reports Inducement Grant Under Nasdaq Rule 5635(c)(4)
18 Jul 2024 //
GLOBENEWSWIRE
Ocular Therapeutix To Present HELIOS Study At ASRS Annual Meeting
10 Jul 2024 //
GLOBENEWSWIRE
Ocular Therapeutic Reports Inducement Grants Under Nasdaq
08 Jul 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Highlights AXPAXLI Enrollment, Wet AMD Repeat Dosing Plan
13 Jun 2024 //
GLOBENEWSWIRE
Ocular Therapeutix® to Host Investor Day on June 13, 2024
05 Jun 2024 //
GLOBENEWSWIRE
Ocular Therapeutix: Reports Nasdaq Inducement Grants
04 Jun 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Inducement Grants Under Nasdaq Rule
06 May 2024 //
GLOBENEWSWIRE
Ocular Therapeutix„ Reports First Quarter 2024 Results
06 May 2024 //
GLOBENEWSWIRE
Ocular Therapeutix„ to Present at Two Upcoming Investor Conferences
06 May 2024 //
GLOBENEWSWIRE
Ocular Therapeutix„ To Present at Two Ophthalmology Meetings, May 4-9, 2024
03 May 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Investor Day In NYC On June 13
01 May 2024 //
GLOBENEWSWIRE
Ocular`s AXPAXLI Shows Positive Phase 1 Diabetic Retinopathy Data
18 Apr 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Strengthens Clinical Team with Retinal Leader Appointments
16 Apr 2024 //
GLOBENEWSWIRE
Ocular Chairman Dugel Now CEO, Mattessich Steps Down
15 Apr 2024 //
GLOBENEWSWIRE
Ocular Thera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Apr 2024 //
GLOBENEWSWIRE
Ocular Announces Positive Ph 2 PAXTRAVA Glaucoma Data at theASCRS
06 Apr 2024 //
GLOBENEWSWIRE
Ocular Therapeutix To Present Data at the 2024 ASCRS Annual Meeting
26 Mar 2024 //
GLOBENEWSWIRE
Ocular Therapeutix„¢ Reports Fourth Quarter and Full Year 2023 Results
11 Mar 2024 //
GLOBENEWSWIRE
Ocular Therapeutix to Release Fourth Quarter and Full Year 2023 Results
05 Mar 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Announces Board of Directors and Leadership Updates
22 Feb 2024 //
GLOBENEWSWIRE
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
22 Feb 2024 //
GLOBENEWSWIRE
Ocular Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 Feb 2024 //
GLOBENEWSWIRE
Ocular Therapeutix„¢ Appoints Steve Meyers to Chief Commercial Officer
15 Feb 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Announces First Subjects Screened in Phase 3 Trial of AXPAXLI
13 Feb 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Announces FDA Agreement to Amend SPA for Trial of AXPAXLI
25 Jan 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Announces Closing of Public Offering of Common Stock
18 Dec 2023 //
GLOBENEWSWIRE
Ocular Therapeutix Announces Proposed Public Offering of Common Stock
13 Dec 2023 //
GLOBENEWSWIRE
Ocular Therapeutix Announces Pricing of Public Offering of Common Stock
13 Dec 2023 //
GLOBENEWSWIRE
Ocular Therapeutix„¢ to Present at Three Upcoming Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
Ocular Therapeutix Provides Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Ocular Therapeutix Receives FDA Agreement Under SPA for First Trial of OTX-TKI
01 Nov 2023 //
GLOBENEWSWIRE
Ocular Therapeutix To Report Third Quarter 2023 Financial Results
24 Oct 2023 //
GLOBENEWSWIRE
Ocular Announces Initiation of its First Trial of OTX-TKI in Wet AMD
03 Oct 2023 //
GLOBENEWSWIRE
Ocular Therapeutix„¢ to Present at Three Upcoming Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Ocular to Present at the H.C. Wainwright 3rd Annual Ophthalmology Conference
09 Aug 2023 //
GLOBENEWSWIRE
Ocular Provides Second Quarter 2023 Financial Results and Corporate Update
07 Aug 2023 //
GLOBENEWSWIRE
Ocular Therapeutix„¢ To Report Second Quarter 2023 Financial Results
24 Jul 2023 //
GLOBENEWSWIRE
Ocular Therapeutix„¢ Announces Appointment of New Board Member
12 Jul 2023 //
GLOBENEWSWIRE
Ocular Therapeutix™ Announces Data from Phase 1 Trial Evaluating OTX-TKI
10 Jun 2023 //
GLOBENEWSWIRE
Ocular Therapeutix Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI
07 Jun 2023 //
GLOBENEWSWIRE
Ocular To Present Top-Line Data from U.S.-Based Phase 1 Trial of OTX-TKI
05 Jun 2023 //
GLOBENEWSWIRE
